Viromed conducts phase I clinical trial for VM202 in China

Published: 2008-12-16 06:40:00

Updated: 2008-12-16 06:40:00

The phase I clinical trial with VM202, a gene-based medicine for treatment of cardiovascular disease (CVD), has been conducted by ViroMed’s China partner Beijing Northland Biotech for peripheral artery disease (PAD, a form of CVD affecting limbs) such as critical limb disease from diabetes and hardening of the arteries, it was announced on December 11.

ViroMed anticipates an expeditious resu...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.